| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Record information and status
Record ID
Date of creation
2014-01-28 16:04 UTC (gutemberg.sousa@mctic.gov.br)
Date of publication
2014-02-11 17:47 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Transformation event
Dr Alexis Henry Gaetan Goux
President of CIBio
Ceva Saúde Animal Ltda (CEVA)
Rua Manuel Joaquim Filho, 303 Pulínia - SP
Paulínia, São Paulo
Brazil, 13140-000
VECTORMUNE® IBD  is a chicken vaccine that contains a genetically engineered Marek's Disease virus of serotype 3 (turkey Herpesvirus or HVT) expressing Infectious Bursal Disease key protective antigens, therefore providing immunity against IBD.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Meleagrid alphaherpesvirus 1 - Turkey herpesvirus, Meleagrid herpesvirus 1
Characteristics of the transformation process
Techniques used for the modification
  • Homologous Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Beta-actin gene promoter - Gallus gallus - Chicken, CHICK
Viral Protein 2 gene - Infectious bursal disease virus - Gumboro virus
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
A 2.9 kb region of the HVT genome was inserted into the pUC18 vector. This fragment contained the incomplete open reading frame (ORF) of UL44 and the complete ORFs of UL45 and UL46 from the HVT genome.

The chicken beta-actin promoter and transcription termination sequences from SV40 and UL46 were inserted into the HVT genoming DNA fragment.

The VP2 gene from the Delaware Variant of the IBDV was amplified from viral RNA using RT-PCR and inserted in to the pUC18 vector in between the beta-actin promoter and termination sequences from SV40 and UL46.

This construct and the the parental HVT strain were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.

Viral particles were cultivated from the chicken embryo fibroblasts and plaques were expanded and screened and selected for the expression of the VP2 gene.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine
Additional Information
Other relevant website address or attached documents

Records referencing this document (7)
7record(s) found
Country's Decision or any other Communication3 records
Modified Organism1 record
Risk Assessment3 records